{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:23:43Z","timestamp":1761740623569,"version":"build-2065373602"},"posted":{"date-parts":[[2025,10,29]]},"group-title":"In Review","reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,2]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Patients with myelodysplastic syndrome (MDS)\/acute myeloid leukemia (AML) with high-risk features including\n                  <italic>TP53<\/italic>\n                  mutations have poor outcomes due to lack of effective therapies. The atypical chemokine surface receptor C-C motif chemokine receptor-like 2 (CCRL2) is overexpressed in MDS and secondary AML (sAML) compared to healthy hematopoietic cells and we recently found that\n                  <italic>TP53<\/italic>\n                  -mutated MDS\/AML and AML with erythroid features express the highest levels of this receptor across MDS\/AML subtypes. To illustrate the therapeutic potential of CCRL2 as a therapeutic target, we developed an anti-CCRL2 antibody-drug conjugate (ADC) by conjugating an anti-CCRL2 antibody with the cytotoxic drug pyrrolobenzodiazepine (PBD), which causes DNA double-strand breaks leading to cancer cell death. The anti-CCRL2 ADC demonstrated strong CCRL2-selective cytotoxicity against cell lines derived from MDS\/AML patients with\n                  <italic>TP53<\/italic>\n                  mutations and erythroid features, surpassing the cytotoxic effects observed with gemtuzumab and PBD-conjugated anti-CD33 and anti-CD123 ADCs. It also induced apoptosis and suppressed the clonogenicity of primary MDS\/AML bone marrow samples without affecting the survival, differentiation and clonogenicity of healthy hematopoietic stem and progenitor cells. This agent also suppressed the leukemic growth of\n                  <italic>TP53-<\/italic>\n                  mutated MDS\/AML cell line xenografts, improving mice survival and decreasing the leukemic burden in patient-derived\n                  <italic>TP53<\/italic>\n                  -mutated MDS\/AML xenografts. In conclusion, our study introduces CCRL2 as a potential new therapeutic target in high-risk MDS\/AML.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7763372\/v1","type":"posted-content","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:41:47Z","timestamp":1761720107000},"source":"Crossref","is-referenced-by-count":0,"title":["A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS\/AML"],"prefix":"10.21203","author":[{"given":"Theodoros","family":"Karantanos","sequence":"first","affiliation":[{"name":"TKARANT1@JHMI.EDU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour","family":"Naji","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha","family":"Ahmedna","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-6881","authenticated-orcid":false,"given":"J","family":"Peske","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghan","family":"Zeng","sequence":"additional","affiliation":[{"name":"johns hopkins university"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandy","family":"Perkins","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zansh\u00e9","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, The Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Nichakawade","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum","family":"Lee","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangeline","family":"Watson","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora","family":"Chatzilygeroudi","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Paun","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Klausner","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuju","family":"An","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teodora","family":"Supeanu","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"Johns Hokins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy","family":"DeZern","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Levis","sequence":"additional","affiliation":[{"name":"John Hopkins"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-7060","authenticated-orcid":false,"given":"Linda","family":"Resar","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard John","family":"Jones","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Styliani","family":"Karanika","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-3702","authenticated-orcid":false,"given":"Suman","family":"Paul","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"2","key":"ref1","first-page":"339","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","author":"Kr\u00f6ger N","year":"2025","unstructured":"Kr\u00f6ger N. Treatment of high-risk myelodysplastic syndromes. Haematologica. 2025;110(2):339\u201349.","journal-title":"Haematologica"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions","volume":"12","author":"Daver NG","year":"2022","unstructured":"Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, et al. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022;12(11):2516\u201329.","journal-title":"Cancer Discov"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41375-023-01985-y","article-title":"Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification","volume":"37","author":"Hochman MJ","year":"2023","unstructured":"Hochman MJ, Othus M, Hasserjian RP, Ambinder A, Brunner A, Percival MM, et al. Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification. Leukemia. 2023;37(9):1915\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu Z","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul S","year":"2024","unstructured":"Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Wright KM, et al. Cancer therapy with antibodies. Nat Rev Cancer. 2024;24(6):399\u2013426.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"ref6","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta E","year":"2022","unstructured":"Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. Blood. 2022;140(4):303\u20138.","journal-title":"Blood"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"20","key":"ref8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman SD","year":"2023","unstructured":"Freeman SD, Thomas A, Thomas I, Hills RK, Vyas P, Gilkes A, et al. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial. Blood. 2023;142(20):1697\u2013707.","journal-title":"Blood"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun Y","year":"2018","unstructured":"Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848\u201358.","journal-title":"Blood Adv"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-023-00910-x","article-title":"Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia","volume":"13","author":"Awada H","year":"2023","unstructured":"Awada H, Abdelmalek M, Cronin T, Baron J, Kashour Z, Azad F, et al. Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia. Blood Cancer J. 2023;13(1):131.","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"615031","DOI":"10.3389\/fcell.2020.615031","article-title":"Del Prete A. Molecular Basis for CCRL2 Regulation of Leukocyte Migration","volume":"8","author":"Schioppa T","year":"2020","unstructured":"Schioppa T, Sozio F, Barbazza I, Scutera S, Bosisio D, Sozzani S, Del Prete A. Molecular Basis for CCRL2 Regulation of Leukocyte Migration. Front Cell Dev Biol. 2020;8:615031.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/2326-6066.CIR-19-0168","article-title":"The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance","volume":"7","author":"Prete A","year":"2019","unstructured":"Del Prete A, Sozio F, Schioppa T, Ponzetta A, Vermi W, Calza S, et al. The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance. Cancer Immunol Res. 2019;7(11):1775\u201388.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood-2017-04-777680","article-title":"The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage","volume":"130","author":"Prete A","year":"2017","unstructured":"Del Prete A, Mart\u00ednez-Mu\u00f1oz L, Mazzon C, Toffali L, Sozio F, Za L, et al. The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage. Blood. 2017;130(10):1223\u201334.","journal-title":"Blood"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"eabl8952","DOI":"10.1126\/sciadv.abl8952","article-title":"The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia","volume":"8","author":"Karantanos T","year":"2022","unstructured":"Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, et al. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Sci Adv. 2022;8(7):eabl8952.","journal-title":"Sci Adv"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3324\/haematol.2022.281444","article-title":"CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine","volume":"108","author":"Karantanos T","year":"2023","unstructured":"Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, et al. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. Haematologica. 2023;108(7):1886\u201399.","journal-title":"Haematologica"},{"key":"ref16","article-title":"C-C motif chemokine receptor-like 2 promotes the interferon-\u03b3 signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53","author":"Naji NS","year":"2025","unstructured":"Naji NS, Pasca S, Chatzilygeroudi T, Toledano-Sanz P, Rimando J, An Y, et al. C-C motif chemokine receptor-like 2 promotes the interferon-\u03b3 signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53. Haematologica. 2025.","journal-title":"Haematologica"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira A","year":"2023","unstructured":"Rodriguez-Meira A, Norfo R, Wen S, Ch\u00e9deville AL, Rahman H, O'Sullivan J, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55(9):1531\u201341.","journal-title":"Nat Genet"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang B","year":"2024","unstructured":"Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, et al. Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun. 2024;15(1):1821.","journal-title":"Nat Commun"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/leu.2013.372","article-title":"An MDS xenograft model utilizing a patient-derived cell line","volume":"28","author":"Rhyasen GW","year":"2014","unstructured":"Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line. Leukemia. 2014;28(5):1142\u20135.","journal-title":"Leukemia"},{"issue":"8007","key":"ref20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade TD","year":"2024","unstructured":"Nichakawade TD, Ge J, Mog BJ, Lee BS, Pearlman AH, Hwang MS, et al. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. Nature. 2024;628(8007):416\u201323.","journal-title":"Nature"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley JA","year":"2018","unstructured":"Hartley JA, Flynn MJ, Bingham JP, Corbett S, Reinert H, Tiberghien A, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Scientific Reports. 2018;8(1):10479.","journal-title":"Scientific Reports"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi F","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094\u2013105.","journal-title":"Blood"},{"issue":"19","key":"ref23","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani M","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634\u201345.","journal-title":"Blood"},{"issue":"20","key":"ref24","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani Y","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"106860","DOI":"10.1016\/j.leukres.2022.106860","article-title":"Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy","volume":"118","author":"Tashakori M","year":"2022","unstructured":"Tashakori M, Wang W, Kadia TM, Daver NG, Montalban-Bravo G, Loghavi S, et al. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res. 2022;118:106860.","journal-title":"Leuk Res"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan N","year":"2017","unstructured":"Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, et al. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia. 2017;31(5):1059\u201368.","journal-title":"Leukemia"},{"issue":"17","key":"ref27","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel G","year":"2016","unstructured":"Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157\u201360.","journal-title":"Blood"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","article-title":"Inotuzumab Ozogamicin for Relapsed\/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22","volume":"27","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, et al. Inotuzumab Ozogamicin for Relapsed\/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021;27(10):2742\u201354.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein EM","year":"2018","unstructured":"Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018;131(4):387\u201396.","journal-title":"Blood"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland MS","year":"2013","unstructured":"Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455\u201363.","journal-title":"Blood"},{"issue":"9825","key":"ref31","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne S","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi F","year":"2020","unstructured":"Ravandi F, Walter R, Subklewe M, B\u00fccklein V, Jongen-Lavrencic M, Paschka P, et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). Journal of Clinical Oncology. 2020;38:7508-.","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"ref33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial","volume":"142","author":"Shah NN","year":"2023","unstructured":"Shah NN, Tasian SK, Kohler ME, Hsieh EM, Baumeister SHC, Summers C, et al. CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial. Blood. 2023;142(Supplement 1):771-.","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1501329","DOI":"10.3389\/fimmu.2025.1501329","article-title":"Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model","volume":"16","author":"Wang T","year":"2025","unstructured":"Wang T, Quijada D, Ahmedna T, Castillo JR, Naji NS, Peske JD, et al. Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model. Front Immunol. 2025;16:1501329.","journal-title":"Front Immunol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7763372\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7763372\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:42:15Z","timestamp":1761720135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7763372\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":34,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7763372\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,10,29]]},"subtype":"preprint"}}